Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial

被引:24
|
作者
Cook, Cheryl [3 ,4 ]
Fay, Sherri [3 ,4 ]
Rockwood, Kenneth [1 ,2 ]
机构
[1] Dalhousie Univ, Div Geriatr Med, Halifax, NS B3H 2E1, Canada
[2] Capital Dist Hlth Author, Div Geriatr Med, Halifax, NS, Canada
[3] Capital Dist Hlth Author, Geriatr Med Res Unit, Halifax, NS, Canada
[4] Dalhousie Univ, Geriatr Med Res Unit, Halifax, NS B3H 2E1, Canada
基金
加拿大健康研究院;
关键词
initiation; Alzheimer's disease; galantamine; phenomenology;
D O I
10.1017/S1041610208007230
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Decreased initiation of activities is a common symptom in Alzheimer's disease (AD) and creates significant burden for carers, yet little is known about how patients, carers and treating physicians describe this problem. Methods: This is a secondary, qualitative analysis of video-recorded, semi-structured and open-ended interviews with the 130 community-dwelling patients with mild-to-moderate AD from the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) study - a four-month, randomized, placebo-controlled trial of galantamine. Interviews were coded and organized using Atlas.ti. By applying a framework analysis approach, patient/carer descriptions of dementia-related decreased initiation of usual tasks and activities were categorized and summarized. Results: Decreased initiation of instrumental activities of daily living (IADLs) and/or leisure and social activities was reported in 85/130 patients at baseline, 71 (84%) of whom specifically targeted increased initiation as a goal of treatment. The most common manifestations of decreased initiation were initiating only with prompting (55%), and no longer initiating but willing to engage in the activity (42%; note that these groups can overlap). Many patients were also described as having less interest (44%) or impaired performance (34%) in the activity in which decreased initiation was noted. Coping strategies were employed by 69/85 carers, most commonly verbal prompts to begin an activity. Conclusion: Decreased initiation is a common and problematic symptom in people with mild-to-moderate Alzheimer's disease who seek treatment for dementia. Information offered voluntarily about interest in or ability to perform activities which are initiated less often gives additional data compared with routine questioning about initiation of function. This is a potentially rich area for the elucidation of disease and treatment effects.
引用
收藏
页码:952 / 963
页数:12
相关论文
共 50 条
  • [31] Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease
    Bennett, James
    Burns, Jeffrey
    Welch, Paul
    Bothwell, Rebecca
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (04) : 1179 - 1187
  • [32] Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
    Merve Güner
    Arzu Okyar Baş
    Serdar Ceylan
    Zeynep Kahyaoğlu
    Süheyla Çöteli
    Pelin Ünsal
    Çağatay Çavuşoğlu
    Cemile Özsürekci
    Burcu Balam Doğu
    Mustafa Cankurtaran
    Meltem Gülhan Halil
    BMC Geriatrics, 23
  • [33] Altered ionized magnesium levels in mild-to-moderate Alzheimer's disease
    Barbagallo, Mario
    Belvedere, Mario
    Di Bella, Giovanna
    Dominguez, Ligia J.
    MAGNESIUM RESEARCH, 2011, 24 (03) : S115 - S121
  • [34] Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer’s Disease
    Adeline Gallini
    Virginie Gardette
    Bruno Vellas
    Maryse Lapeyre-Mestre
    Sandrine Andrieu
    Christine Brefel-Courbon
    Drugs & Aging, 2013, 30 : 439 - 445
  • [35] Results of an open clinical trial of rivastigmine in mild and moderate Alzheimer's disease
    Dennler, HJ
    Retz, W
    Rösler, M
    PSYCHOPHARMAKOTHERAPIE, 2001, 8 (03): : 111 - 117
  • [36] Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial
    Quintana-Hernandez, Domingo J.
    Rojas-Hernandez, Jaime
    Santana-Del Pino, Angelo
    Cespedes Suarez, Carmen
    Pellejero Silva, Monica
    Teresa Miro-Barrachina, Maria
    Ibanez Fernandez, Ignacio
    Estupinan Lopez, Jose Antonio
    Borkel, Lucas F.
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 91 (01) : 471 - 481
  • [37] Rivastigmine Transdermal Patch Skin TolerabilityResults of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer’s Disease
    Jeffrey L. Cummings
    Martin R. Farlow
    Xiangyi Meng
    Sibel Tekin
    Jason T. Olin
    Clinical Drug Investigation, 2010, 30 : 41 - 49
  • [38] Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease
    Egan, Michael F.
    Mukai, Yuki
    Voss, Tiffini
    Kost, James
    Stone, Julie
    Furtek, Christine
    Mahoney, Erin
    Cummings, Jeffrey L.
    Tariot, Pierre N.
    Aisen, Paul S.
    Vellas, Bruno
    Lines, Christopher
    Michelson, David
    ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (01)
  • [39] Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
    Michael F. Egan
    Yuki Mukai
    Tiffini Voss
    James Kost
    Julie Stone
    Christine Furtek
    Erin Mahoney
    Jeffrey L. Cummings
    Pierre N. Tariot
    Paul S. Aisen
    Bruno Vellas
    Christopher Lines
    David Michelson
    Alzheimer's Research & Therapy, 11
  • [40] Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD
    Dyer, Adam H.
    Lawlor, Brian
    Kennelly, Sean P.
    Lawlor, Brian
    BMC GERIATRICS, 2020, 20 (01)